Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer

The 2017 PACIFIC trial heralded the incorporation of routine adjuvant durvalumab following curative-intent chemoradiation for stage III non-small-cell lung cancer (NSCLC). However, carefully selected clinical trial populations can differ significantly from real-world populations, which can have impl...

Descripción completa

Detalles Bibliográficos
Autores principales: Preti, Beatrice T. B., Sanatani, Michael S., Breadner, Daniel, Lakkunarajah, Suganija, Scott, Carolyn, Esmonde-White, Caroline, McArthur, Eric, Rodrigues, George, Chaudhary, Mitali, Mutsaers, Adam, Sachdeva, Robin, Vincent, Mark D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453685/
https://www.ncbi.nlm.nih.gov/pubmed/37623040
http://dx.doi.org/10.3390/curroncol30080559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453685/
https://www.ncbi.nlm.nih.gov/pubmed/37623040
http://dx.doi.org/10.3390/curroncol30080559

Ejemplares similares